New commercial

[liane]

Was just listening to a commercial - imagine if there was a new class of medication to lower your blood sugar and control your A1c. Darn! - It was for Invokana.

[Chris]

Johnson & Johnson’s Invokana (generic name canagliflozin)

Doesn't this hurt MNKD's possibility of partnering with J&J as doing such may cannibalize there product and spread thin staff and their market focus?

For those interested in Invokana:
www.forbes.com/sites/melaniehaiken/2013/04/01/invokana-a-potential-blockbuster-diabetes-drug-approved-by-the-fda/

[ezrasfund]

Looking at which Pharma might benefit most from partnership I always come back to Sanofi and Lantus. Here is another question for the physicians and others who are willing to look deeper into the data. Afrezza prevents the "stacking" effect of other prandial insulins, and so in the MK171 trial the Afrezza arm was titrated to a higher dose of basal insulin. Just how much higher? Could this be another aspect of treatment with Afrezza that would potentially increase sales of Lantus? And Lantus is still "the basal insulin shown to be effective with Afrezza in clinical trials".